NCT03120364.

Trial name or title	Immunogenicity and safety of NBP608 compared to Zostavax in healthy adult aged 50 and over
Methods	Phase 3 Allocation: randomised Intervention model: parallel assignment Blinding: double‐blind (participant, investigator) Primary purpose: prevention
Participants	824 healthy participants aged 50 years and over
Interventions	NBP608 LZV (preparation of Oka/SK strain of live attenuated zoster virus) Zostavax
Outcomes	Immunogenicity and safety
Starting date	September 2015
Contact information	Hee‐Jin Cheong PhD, Korea University Guro Hospital
Notes	Completed (April 2016), but no results posted on ClinicalTrials.gov and no publications identified Primary completion date: December 2015 "Launched for Herpes zoster (In the elderly, Prevention, In volunteers, In adults) in South Korea (SC) before May 2018" adisinsight.springer.com/drugs/800049347 Sponsor: SK Chemicals Co Ltd